Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve (NASDAQ:ZBIO)
· seekingalpha.com
Zenas BioPharma is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date. Read why ZBIO stock is a Buy.
I last covered Zenas BioPharma ( ZBIO ) in July, a little under three months ago, when the obexelimab BLA had just been submitted. Since then, the FDA has accep...